Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: The biguanides and the prevention of the risk of obesity (BIGPRO) 1 study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 3, 2001, Pages 407-414

  Bard, J M ^a,b   Charles, M A ^a   Juhan Vague, I ^a   Vague, P ^a   Andre P ^a   Safar, M ^a   Fruchart, J C ^a   Eschwege, E ^a  

^a INSERM   (France)

^b Departement de Sante Publique   (France)

Author keywords

Apolipoproteins; Central fat distribution; Insulin resistance syndrome; Lipoprotein particles; Triglyceride rich lipoproteins

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BIGUANIDE DERIVATIVE; LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIUM LESION; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035098061     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.21.3.407     Document Type: Article

References (47)

1. Portal adipose tissue as a generator of risk factors for cardiovascular disease and diabetes
2. Insulin resistance in visceral obesity
3. The deadly quartet: Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension
4. Insulin resistance: A secret killer?
5. Role of insulin resistance in human disease
6. Increased plasma plasminogen activator inhibitor 1 levels: A possible link between insulin resistance and atherothrombosis
7. Apoprotein composition of very low density lipoproteins of human serum
8. Dynamics of apolipoprotein E metabolism in humans
9. Very low density lipoprotein: Fate of phospholipids, cholesterol, and apolipoprotein C during lipolysis in vitro
10. Changes in the plasma lipoprotein distribution of apolipoproteins C-II, C-III1, C-II12 and apolipoprotein B after heparin-induced lipolysis
11. Effect of lipoprotein lipase and hepatic triglyceride lipase activity on the distribution of apolipoprotein E among plasma lipoproteins
12. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
13. Modulation of lipoprotein lipase activity by apolipoproteins: Effect of apolipoprotein C-III
14. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: Implications for the regulation of the catabolism of these lipoproteins
15. Enhanced binding by cultured human fibroblasts of apo E-containing lipoproteins as compared with low density lipoproteins
16. Apolipoprotein E: Structure-function relationships
17. Mechanisms of inhibition of apolipoprotein C on apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway
18. Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells
19. Clearance of chylomicron remnants by the low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor
20. David Rubinstein Memorial Lecture: The biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins
21. Distribution of C-II and C-III peptides in lipoprotein classes: Methods and clinical significance
22. Lipoprotein abnormalities in chronic haemodialysis patients
23. Apolipoproteins C-III and E in apo B- and non-apo B-containing lipoproteins in two populations at contrasting risk for myocardial infarction: The ECTIM study
24. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts
25. Triglyceride and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin
26. Coronary artery disease and triglyceride-enriched lipoproteins
27. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution
28. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge
29. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay
30. Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody based enzyme linked immunosorbent assay
31. Assay of human tissue type plasminogen activator (t-PA) with an enzyme linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA
32. Detection and management of lipid disorders in diabetes
33. Coronary heart disease: Reducing the risk: A worldwide view
34. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
35. Von Willebrand factor and the endothelium in vascular disease
36. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes
37. Hyperinsulinemia and triglyceride-rich lipoproteins
38. Postprandial triglyceride response in visceral obesity in men
39. Gender difference in postprandial lipemia: Importance of visceral adipose tissue accumulation
40. Metabolic heterogeneity associated with high plasma triglyceride or low HDL cholesterol levels in men
41. Plasma high-density lipoprotein cholesterol but not apolipoprotein A-I is a good correlate of the visceral obesity-insulin resistance dyslipidemic syndrome
42. Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension
43. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: Studies in randomly selected normo and hypertriglyceridaemic men
44. Increased plasma plasminogen activator inhibitor-1 levels: A possible link between insulin resistance and atherothrombosis
45. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells induced by very low density lipoprotein
46. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in hepG2 cells are regulated by VLDL